Research Topics
Genomes and Genes | Yoshihiro KomoharaSummaryAffiliation: Kumamoto University Country: Japan Publications
| Collaborators
|
Detail Information
Publications
HLA-G as a target molecule in specific immunotherapy against renal cell carcinomaYoshihiro Komohara
Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
Oncol Rep 18:1463-8. 2007..These results indicate that HLA-G-associated immunoregulation can be overcome and that HLA-G peptide-based anti-cancer immunotherapy is feasible...
Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosisNobuyo Higashi-Kuwata
Department of Dermatology and Plastic and Reconstructive Surgery, Kumamoto University, Kumamoto, Japan
Arthritis Res Ther 12:R128. 2010....- Identification of target antigens in specific immunotherapy for renal cell carcinomaYoshihiro Komohara
Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University, Fukuoka, Japan
J Urol 177:1157-62. 2007.... 
Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patientsMingyue Jin
Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka 830 0011, Japan
Cancer Sci 99:1656-62. 2008..g. lung, colon, stomach, liver and pancreatic) cells. Taken together, the two peptides derived from EphB6v might be appropriate targets for peptide-based specific immunotherapy for HLA-A2(+) patients with various cancers...- Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patientsShigetaka Suekane
Department of Urology, Kurume University School of Medicine, Fukuoka 830 0011, Japan
Cancer Sci 98:1965-8. 2007..These results encourage further clinical trials of personalized peptide vaccinations... - A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA allelesYamei Niu
Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
J Med Virol 81:1232-40. 2009..These results may provide new insights for the development of a novel peptide vaccine against HCV compatible with various HLA class IA types... - New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patientsYukoh Itoh
Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
Oncol Rep 18:1231-7. 2007..These results indicate that these EZH2 120-128 and EZH2 165-174 peptides could be promising candidates in peptide-based immunotherapy for HLA-A2+ prostate cancer patients... - Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinomaYoshihiro Komohara
Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
Int J Oncol 29:1555-60. 2006..IgG reactive to the SART3109-118 peptide was frequently detected in the plasma of BC patients. This information could facilitate the development of effective peptide-based immunotherapy for HLA-A24+ BC patients... - Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patientsMingyue Jin
Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka 830 0011, Japan
Oncol Rep 19:1277-83. 2008..Taken together, the two peptides derived from the variant of EphB6 might be appropriate targets for peptide-based specific immunotherapy to HLA-A24(+) patients with malignant glioma... - Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancerMasanori Noguchi
Department of Urology, Kurume University School of Medicine, Kurume, Japan
Prostate 67:933-42. 2007..The purpose of this study was to determine the safety and immune responses of pre-operative personalized peptide vaccine for patients with localized prostate cancer... - Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancerShigenori Homma
Department of Immunology, Kurume University School of Medicine, Fukuoka 830 0011, Japan
Oncol Rep 18:343-6. 2007.... - Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapyKoichi Azuma
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
Cancer Sci 98:1336-43. 2007.... - High expression of APOBEC3G in patients infected with hepatitis C virusYoshihiro Komohara
Department of Immunology, Kurume University School of Medicine, Asahi machi 67, Kurume, Fukuoka 839 0011, Japan
J Mol Histol 37:327-32. 2006..Incubation of the cells with interferon also resulted in the augmentation. These results may provide new insight into the pathogenesis of chronic HCV infection...